BioMarin Provides Update on FDA Review of ROCTAVIAN™ (Valoctocogene Roxaparvovec) Gene Therapy for Adults with Severe Hemophilia A

/PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today...

Related Keywords

Hank Fuchs ,Marni Kottle ,Traci Mccarty ,Development Of Biomarin ,European Commission ,Drug Administration ,Biomarin Pharmaceutical Inc ,Nasdaq ,Exchange Commission ,Worldwide Research ,Prnewswire Biomarin Pharmaceutical Inc ,European Medicines Agency ,Robust Clinical Program ,Target Action Date ,Marin Pharmaceutical ,Biologics License Application ,Major Amendment ,Action Date ,Pre License Inspection ,Regenerative Medicine Advanced Therapy ,Breakthrough Therapy ,Orphan Drug ,Biomarin Pharmaceutical ,Annual Report ,